What is Virpax Pharmaceuticals, Inc. (VRPX)?

Virpax Pharmaceuticals, Inc. (VRPX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of VRPX?

The current price of VRPX is $0.00. Prices are updated in real time on Stocks360.

What is VRPX's price-to-earnings (PE) ratio?

VRPX's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is VRPX's market capitalization?

VRPX's market capitalization is $994.00, placing it in the small-cap tier.

Virpax Pharmaceuticals, Inc. (VRPX)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$994.00

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.44

Day Range

$0.00 – $0.02

52-wk Range

$0.00 – $0.10

Avg Volume

N/A

Volume

51.00

Virpax Pharmaceuticals, Inc. (VRPX) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $994.00. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $0.02 2026-10-29 · $0.00 (-96.19%)

Earnings

Most Recent

Mar 3, 2025

EPS $-0.80 vs est. $-9.25

Beat by $8.45

Next Earnings

Nov 19, 2026

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineered to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in…